Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Fallopian Tube Cancer symptoms may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis.
The Fallopian Tube Cancer pipeline drugs market research report provides an analysis of the Fallopian Tube Cancer drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects.
Fallopian Tube Cancer Pipeline Drugs Market Segmentation by Targets
Some of the targets of the Fallopian Tube Cancer pipeline drugs market are Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NA, Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor A, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase) Diphtheria Toxin Like 2 or NAD, Tubulin, Vascular Endothelial Growth Factor Receptor 2, and Mast/Stem Cell Growth Factor Receptor Kit among others.
Fallopian Tube Cancer Pipeline Drugs Market Analysis, by Targets
To know more about the targets in the Fallopian Tube Cancer pipeline drugs market , download a free report sample
Fallopian Tube Cancer Pipeline Drugs Market Segmentation by Mechanisms of Action
The mechanisms of action of the Fallopian Tube Cancer pipeline drugs market are Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria) Toxin Like 1 or NAD Inhibitor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor A Inhibitor, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD Inhibitor, Tubulin Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor among others.
Fallopian Tube Cancer Pipeline Drugs Market Analysis, by Mechanisms of Action
To know more about the MoA in the Fallopian Tube Cancer pipeline drugs market , download a free report sample
Fallopian Tube Cancer Pipeline Drugs Market Segmentation by Routes of Administration
The routes of administration in the Fallopian Tube Cancer pipeline drugs market are intravenous, oral, subcutaneous, intraperitoneal, intravenous drip, parenteral, intradermal, intratumor, intravesical, and intralesional among others.
Fallopian Tube Cancer Pipeline Drugs Market Analysis, by Routes of Administration
To know more about the RoA in the Fallopian Tube Cancer pipeline drugs market , download a free report sample
Fallopian Tube Cancer Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Fallopian Tube Cancer pipeline drugs market are Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Cell Therapy, Gene-Modified Cell Therapy, Fusion Protein, Subunit Vaccine, Oncolytic Virus, and Oligonucleotide among others.
Fallopian Tube Cancer Pipeline Drugs Market Analysis, by Molecule Types
To know more about the molecules in the Fallopian Tube Cancer pipeline drugs market , download a free report sample
Leading Companies in the Fallopian Tube Cancer Pipeline Drugs Market
Some of the leading companies in the Fallopian Tube Cancer pipeline drugs market are AstraZeneca Plc, GSK plc, Pfizer Inc, Advenchen Laboratories LLC, CSPC Pharmaceutical Group Ltd, Pharma Mar SA, Bayer AG, Bristol-Myers Squibb Co, Eisai Co Ltd, F. Hoffmann-La Roche Ltd, and Merck KGaA among others.
Fallopian Tube Cancer Pipeline Drugs Market Analysis, by Leading Companies
To know more about the leading companies in the Fallopian Tube Cancer pipeline drugs market , download a free report sample
Fallopian Tube Cancer Pipeline Drugs Market Report Overview
Key Targets | Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NA, Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor A, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase) Diphtheria Toxin Like 2 or NAD, Tubulin, Vascular Endothelial Growth Factor Receptor 2, and Mast/Stem Cell Growth Factor Receptor Kit |
Key Mechanisms of Action | Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria) Toxin Like 1 or NAD Inhibitor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor A Inhibitor, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD Inhibitor, Tubulin Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor |
Key Routes of Administration | Intravenous, Oral, Subcutaneous, Intraperitoneal, Intravenous Drip, Parenteral, Intradermal, Intratumor, Intravesical, and Intralesional |
Key Molecule Types | Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Cell Therapy, Gene-Modified Cell Therapy, Fusion Protein, Subunit Vaccine, Oncolytic Virus, and Oligonucleotide |
Key Companies | AstraZeneca Plc, GSK plc, Pfizer Inc, Advenchen Laboratories LLC, CSPC Pharmaceutical Group Ltd, Pharma Mar SA, Bayer AG, Bristol-Myers Squibb Co, Eisai Co Ltd, F. Hoffmann-La Roche Ltd, and Merck KGaA |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
AbbVie Inc
ADC Therapeutics SA
Advenchen Laboratories LLC
AiVita Biomedical Inc
Akeso Inc
Aldeyra Therapeutics Inc
Alkermes Plc
Alpine Immune Sciences Inc
Amgen Inc
Aminex Therapeutics Inc
Anixa Biosciences Inc
Apexigen Inc
APIM Therapeutics AS
Apollomics Inc
Aprea Therapeutics Inc
Aravive Inc
Arch Oncology Inc
Artios Pharma Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Basilea Pharmaceutica Ltd
Bayer AG
BeiGene Ltd
Bio-Path Holdings Inc
Bio-Thera Solutions Ltd
BioAtla Inc
BioIntegrator
BioInvent International AB
BioNTech SE
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Celldex Therapeutics Inc
Celltrion Inc
Celsion Corp
Clovis Oncology Inc
Coherent Biopharma
Compugen Ltd
Corcept Therapeutics Inc
Cotinga Pharmaceuticals Inc
Cristal Therapeutics BV
CSPC Pharmaceutical Group Ltd
Daiichi Sankyo Co Ltd
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Co
Ellipses Pharma Ltd
ENB Therapeutics LLC
Exelixis Inc
F. Hoffmann-La Roche Ltd
FUJIFILM Toyama Chemical Co Ltd
Genelux Corp
Genentech USA Inc
Genmab AS
Gilead Sciences Inc
Gradalis Inc
Greenfire Bio LLC
GSK plc
Harpoon Therapeutics Inc
Hutchison MediPharma Ltd
I-Mab
Idience Co Ltd
ImmunityBio Inc
Immunocore Limited
ImmunoGen Inc
Immunotech Biopharm Ltd
IMPACT Therapeutics Inc
IMV Inc
Incyte Corp
Innovent Biologics Inc
Instil Bio Inc
InxMed (Beijing) Co Ltd
Ipsen SA
Jiangsu Hengrui Medicine Co Ltd
Jina Pharmaceuticals Inc
Johnson & Johnson
Karyopharm Therapeutics Inc
Kidswell Bio Corp
Laekna Therapeutics Shanghai Co Ltd
Leap Therapeutics Inc
Lee's Pharmaceutical Holdings Ltd
Lokon Pharma AB
MabVax Therapeutics Holdings Inc
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
Mersana Therapeutics Inc
Mina Therapeutics Ltd
Mycenax Biotech Inc
Northlake International LLC
Novartis AG
NuCana Plc
Nurix Therapeutics Inc
Nuvation Bio Inc
OBI Pharma Inc
OncoC4 Inc
Oncoinvent AS
Onconic Therapeutics Co Ltd
OncoQuest Inc
Oncovir Inc
OncXerna Therapeutics Inc
Ono Pharmaceutical Co Ltd
Onxeo SA
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
Pharmicell Co Ltd
Pharos iBio Co Ltd
Pionyr Immunotherapeutics Inc
Plexxikon Inc
Precigen Inc
Prestige BioPharma Ltd
ProLynx LLC
PsiOxus Therapeutics Ltd
PTC Therapeutics Inc
R-Pharm US LLC
Recordati SpA
Regeneron Pharmaceuticals Inc
RemeGen Co Ltd
Rhizen Pharmaceuticals SA
Rigel Pharmaceuticals Inc
Samyang Biopharmaceuticals Corp
Sanofi
Scancell Holdings Plc
Seagen Inc
SELLAS Life Sciences Group Inc
Senhwa Biosciences Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shattuck Labs Inc
Shenzhen Chipscreen Biosciences Co Ltd
Sorrento Therapeutics Inc
STADA Pharmaceuticals (Asia) Ltd
Sumitomo Pharma Co Ltd
Sutro Biopharma Inc
Synermore Biologics Co Ltd
SynOx Therapeutics Ltd
TILT Biotherapeutics Ltd
Tmunity Therapeutics Inc
Toray Industries Inc
Transgene SA
Ultimovacs AS
Vascular Biogenics Ltd
Verastem Inc
Viatris Inc
Vigeo Therapeutics Inc
Vivesto AB
Vyriad Inc
Xencor Inc
Xynomic Pharmaceuticals Holdings Inc
Zenith Epigenetics Ltd
Zentalis Pharmaceuticals Inc
Zymeworks Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the Fallopian Tube Cancer pipeline drugs market?
Some of the targets of the Fallopian Tube Cancer pipeline drugs market are Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NA, Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor A, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase) Diphtheria Toxin Like 2 or NAD, Tubulin, Vascular Endothelial Growth Factor Receptor 2, and Mast/Stem Cell Growth Factor Receptor Kit among others.
-
What are the mechanisms of action of the Fallopian Tube Cancer pipeline drugs market?
The key mechanism of action of the Fallopian Tube Cancer pipeline drugs market are Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria) Toxin Like 1 or NAD Inhibitor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor A Inhibitor, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD Inhibitor, Tubulin Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor among others.
-
What are the top routes of administration in the Fallopian Tube Cancer pipeline drugs market?
The routes of administration in the Fallopian Tube Cancer pipeline drugs market are intravenous, oral, subcutaneous, intraperitoneal, intravenous drip, parenteral, intradermal, intratumor, intravesical, and intralesional among others.
-
What are the molecule types in the Fallopian Tube Cancer pipeline drugs market?
The molecule types in the Fallopian Tube Cancer pipeline drugs market are Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Cell Therapy, Gene-Modified Cell Therapy, Fusion Protein, Subunit Vaccine, Oncolytic Virus, and Oligonucleotide among others.
-
Which are the leading companies in the Fallopian Tube Cancer pipeline drugs market?
Some of the leading companies in the Fallopian Tube Cancer pipeline drugs market are AstraZeneca Plc, GSK plc, Pfizer Inc, Advenchen Laboratories LLC, CSPC Pharmaceutical Group Ltd, Pharma Mar SA, Bayer AG, Bristol-Myers Squibb Co, Eisai Co Ltd, F. Hoffmann-La Roche Ltd, and Merck KGaA among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.